| scholarly article | Q13442814 |
| P50 | author | Rory Edwards Collins | Q7366866 |
| John Danesh | Q22277498 | ||
| Sarah Parish | Q86996408 | ||
| P2093 | author name string | Derrick Bennett | |
| Jonathan Emberson | |||
| Jane Armitage | |||
| Emma Link | |||
| P2860 | cites work | Atherosclerosis — An Inflammatory Disease | Q26776972 |
| MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial | Q28214393 | ||
| Inflammation, atherosclerosis, and coronary artery disease | Q29547232 | ||
| Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein | Q29547752 | ||
| Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins | Q29547856 | ||
| Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials | Q29617910 | ||
| The relationship between reduction in low-density lipoprotein cholesterol by statins and reduction in risk of cardiovascular outcomes: an updated meta-analysis | Q33420117 | ||
| MRC/BHF Heart Protection Study of antioxidant vitamin supplementation in 20,536 high-risk individuals: a randomised placebo-controlled trial | Q33960122 | ||
| Reliable assessment of the effects of treatment on mortality and major morbidity, I: clinical trials | Q34157981 | ||
| Reliable assessment of the effects of treatment on mortality and major morbidity, II: observational studies | Q34198010 | ||
| Current concepts of the pathogenesis of the acute coronary syndromes | Q34310339 | ||
| Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial | Q34550538 | ||
| Low-density lipoprotein-dependent and -independent effects of cholesterol-lowering therapies on C-reactive protein: a meta-analysis | Q34629713 | ||
| C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis | Q35182277 | ||
| Chemical, pharmacokinetic and pharmacodynamic properties of statins: an update | Q36014966 | ||
| Stopping randomized trials early for benefit and estimation of treatment effects: systematic review and meta-regression analysis | Q37717921 | ||
| By Jove! What is a clinician to make of JUPITER? | Q37768304 | ||
| Effects of statin therapy according to plasma high-sensitivity C-reactive protein concentration in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA): a retrospective analysis | Q38377634 | ||
| Relation of baseline high-sensitivity C-reactive protein level to cardiovascular outcomes with rosuvastatin in the Justification for Use of statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER). | Q38467359 | ||
| Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial | Q38473723 | ||
| Lipoprotein-associated phospholipase A₂ activity and mass in relation to vascular disease and nonvascular mortality | Q42836650 | ||
| Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events | Q43656468 | ||
| C-reactive protein levels and outcomes after statin therapy | Q45213511 | ||
| Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events (CARE) Investigators. | Q50866439 | ||
| Development and validation of improved algorithms for the assessment of global cardiovascular risk in women: the Reynolds Risk Score. | Q51922378 | ||
| MRC/BHF Heart Protection Study of cholesterol-lowering therapy and of antioxidant vitamin supplementation in a wide range of patients at increased risk of coronary heart disease death: early safety and efficacy experience | Q56336748 | ||
| Long-term effects of pravastatin on plasma concentration of C-reactive protein. The Cholesterol and Recurrent Events (CARE) Investigators | Q78017116 | ||
| P433 | issue | 9764 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | patient | Q181600 |
| statin therapy | Q62562875 | ||
| P304 | page(s) | 469-76 | |
| P577 | publication date | 2011-02-05 | |
| P1433 | published in | The Lancet | Q939416 |
| P1476 | title | C-reactive protein concentration and the vascular benefits of statin therapy: an analysis of 20,536 patients in the Heart Protection Study | |
| P478 | volume | 377 |
| Q36721590 | A Novel Medical Treatment for Lipid Control in Patients with Unstable Angina Pectoris and Statin-Induced Liver Dysfunction. |
| Q38134084 | Almost everyone over 50 should be put on a statin to reduce the risk of cardiovascular disease: A protagonist view. |
| Q34095488 | Anti-inflammatory and anti-thrombogenic effects of atorvastatin in acute ischemic stroke |
| Q92610593 | Association Between Baseline, Achieved, and Reduction of CRP and Cardiovascular Outcomes After LDL Cholesterol Lowering with Statins or Ezetimibe: A Systematic Review and Meta-Analysis |
| Q37000223 | Association of malnutrition-inflammation complex and responsiveness to erythropoiesis-stimulating agents in long-term hemodialysis patients |
| Q35213010 | Associations between C-reactive protein, coronary artery calcium, and cardiovascular events: implications for the JUPITER population from MESA, a population-based cohort study |
| Q90013033 | Atherosclerosis Prediction with High Sensitivity C-Reactive Protein (hs-CRP) and Related Risk Factor in Patient with Dyslipidemia |
| Q38072595 | Between risk charts and imaging: how should we stratify cardiovascular risk in clinical practice? |
| Q83810410 | Biomarkers: Is CRP level useful to guide statin therapy? Lack of evidence from HPS fuels the debate |
| Q84275088 | C-reactive protein in the Heart Protection Study |
| Q57496180 | C-reactive protein in the Heart Protection Study – Authors' reply |
| Q35101153 | C-reactive protein levels in patients at cardiovascular risk: EURIKA study |
| Q37021409 | C-reactive protein, fibrinogen, and cardiovascular disease prediction |
| Q37906353 | C-reactive protein, statins and the risk of vascular events: a better understanding |
| Q95633714 | Clinical approach to the inflammatory etiology of cardiovascular diseases |
| Q38880500 | Clinical relevance for lowering C-reactive protein with statins. |
| Q26764766 | Clinical relevance of high sensitivity C-reactive protein in cardiology |
| Q35153209 | Coexistence of low vitamin D and high fibroblast growth factor-23 plasma levels predicts an adverse outcome in patients with coronary artery disease |
| Q38049066 | Dyslipidemia: management using optimal lipid-lowering therapy |
| Q35757048 | Effect of atorvastatin on C-reactive protein and benefits for cardiovascular disease in patients with type 2 diabetes: analyses from the Collaborative Atorvastatin Diabetes Trial |
| Q45191361 | Effects of low-fat or full-fat fermented and non-fermented dairy foods on selected cardiovascular biomarkers in overweight adults. |
| Q42021710 | Effects of pitavastatin on walking capacity and CD34+/133+ cell number in patients with peripheral artery disease |
| Q44973053 | Effects of rosuvastatin on subclinical atherosclerosis and arterial stiffness in rheumatoid arthritis: a randomized controlled pilot trial |
| Q52886658 | Effects of simvastatin and ezetimibe on interleukin-6 and high-sensitivity C-reactive protein. |
| Q52371615 | Elevated Levels of Serum β2-Glycoprotein I/Oxidized Low-Density Lipoprotein Complexes Are Associated with Cerebral Infarction in Patients with Type 2 Diabetes Mellitus. |
| Q35756468 | Evaluation of C-reactive protein prior to and on-treatment as a predictor of benefit from atorvastatin: observations from the Anglo-Scandinavian Cardiac Outcomes Trial |
| Q38233001 | High-Sensitivity C-Reactive Protein and Statin Initiation. |
| Q34516430 | Homocysteine levels and treatment effect in the PROspective Study of Pravastatin in the Elderly at Risk |
| Q38176273 | How low an LDL-C should we go with statin therapy? |
| Q37586959 | Hypertension in pregnancy is associated with elevated C-reactive protein levels later in life |
| Q26865722 | Identifying novel biomarkers for cardiovascular disease risk prediction |
| Q90389973 | Identifying the anti-inflammatory response to lipid lowering therapy: a position paper from the working group on atherosclerosis and vascular biology of the European Society of Cardiology |
| Q30731532 | Incorporating a Genetic Risk Score Into Coronary Heart Disease Risk Estimates: Effect on Low-Density Lipoprotein Cholesterol Levels (the MI-GENES Clinical Trial) |
| Q37947242 | Inflammatory markers in coronary heart disease |
| Q36637949 | Influence of atherosclerosis-related risk factors on serum high-sensitivity C-reactive protein levels in patients with type 2 diabetes: Comparison of their influence in obese and non-obese patients |
| Q47394637 | Lowering LDL cholesterol reduces cardiovascular risk independently of presence of inflammation |
| Q45822783 | Meta-Analysis Comparing Rosuvastatin and Atorvastatin in Reducing Concentration of C-Reactive Protein in Patients With Hyperlipidemia |
| Q50890395 | Metabolic syndrome in the prediction of cardiovascular events: the potential additive role of hsCRP and adiponectin. |
| Q97559552 | Multimarker approach including CRP, sST2 and GDF-15 for prognostic stratification in stable heart failure |
| Q28073319 | Overcoming Challenges With Statin Therapy |
| Q36247131 | Reducing serum cholesterol levels in women |
| Q100525999 | Reduction in hsCRP levels is associated with decreased incidence of cardiovascular events in Japanese hypertensive women but not in men |
| Q37962460 | Role of C-reactive protein when prescribing a statin |
| Q33922922 | Secondary analysis of APPLE study suggests atorvastatin may reduce atherosclerosis progression in pubertal lupus patients with higher C reactive protein. |
| Q34812017 | Statin therapy after infrainguinal bypass surgery for critical limb ischemia is associated with improved 5-year survival |
| Q36088110 | Statins as anti-inflammatory agents in atherogenesis: molecular mechanisms and lessons from the recent clinical trials. |
| Q24201513 | Statins for the primary prevention of cardiovascular disease |
| Q37883015 | Statins, inflammation and kidney disease |
| Q38462688 | The JUPITER trial: myth or reality? |
| Q41967368 | The effect of periodontal treatment on C-reactive protein: A clinical study. |
| Q38106872 | The immune system in stroke: clinical challenges and their translation to experimental research |
| Q35866695 | The role and clinical significance of high-sensitivity C-reactive protein in cardiovascular disease |
| Q34665888 | Time variability of C-reactive protein: implications for clinical risk stratification |
| Q45125528 | Treatment of patients with intermediate cardiovascular risk: Are clinical measures enough? |
| Q53669745 | Under-reporting of venous and arterial thrombotic events in randomized clinical trials: a meta-analysis. |
| Q39215606 | Vascular inflammation and low-density lipoproteins: is cholesterol the link? A lesson from the clinical trials |
Search more.